Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma

Dutoit, Julie C.; Claus, Eveline; Offner, Fritz; Noens, Lucien; Delanghe, Joris; Verstraete, Koenraad

doi:10.1016/j.ejrad.2015.11.040

Cited by 60 publications

(47 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DCE‐MRI is an emerging imaging technique that allows quantification of various vascular biomarkers . It has been reported to be useful for various applications, such as differentiating lung cancer from benign solitary pulmonary lesions, assessing the different T stage of nasopharyngeal carcinoma, noninvasively evaluating the immature mean vessel density of brain gliomas, and predicting the treatment response for patients with multiple myeloma …”

mentioning

confidence: 99%

“…16 It has been reported to be useful for various applications, such as differentiating lung cancer from benign solitary pulmonary lesions, assessing the different T stage of nasopharyngeal carcinoma, noninvasively evaluating the immature mean vessel density of brain gliomas, and predicting the treatment response for patients with multiple myeloma. [16][17][18][19][20] Therefore, the purpose of this study was to determine the optimal combination of parameters derived from 3T multiparametric MRI (conventional MR, DW, and DCE) for differentiating malignant from benign OLPDs.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Benign and malignant orbital lymphoproliferative disorders: Differentiating using multiparametric MRI at 3.0T

et al. 2016

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Benign and malignant orbital lymphoproliferative disorders: Differentiating using multiparametric MRI at 3.0T

et al. 2016

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

show abstract

“…Novel MRI sequences are now available. For example, diffusion weighted imaging (DWI) and delayed contrast enhancement (DCE) seem to improve the diagnostic properties of MRI in MM patients [59, 60]. Combining PET with these novel MRI techniques may be valuable for optimal diagnosis and evaluation of relapsed MM activity.…”

Section: Discussionmentioning

confidence: 99%

Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting

Waal

Glaudemans

Schröder

et al. 2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Multiple myeloma (MM) is characterized by a monoclonal plasma cell population in the bone marrow. Lytic lesions occur in up to 90 % of patients. For many years, whole-body X-ray (WBX) was the method of choice for detecting skeleton abnormalities. However, the value of WBX in relapsing disease is limited because lesions persist post-treatment, which restricts the capacity to distinguish between old, inactive skeletal lesions and new, active ones. Therefore, alternative techniques are necessary to visualize disease activity. Modern imaging techniques such as magnetic resonance imaging, positron emission tomography and computed tomography offer superior detection of myeloma bone disease and extramedullary manifestations. In particular, the properties of nuclear imaging enable the identification of disease activity by directly targeting the specific cellular properties of malignant plasma cells. In this review, an overview is provided of the effectiveness of radiopharmaceuticals that target metabolism, surface receptors and angiogenesis. The available literature data for commonly used nuclear imaging tracers, the promising first results of new tracers, and our pilot work indicate that a number of these radiopharmaceutical applications can be used effectively for staging and response monitoring of relapsing MM patients. Moreover, some tracers can potentially be used for radio immunotherapy.

show abstract

“…Very recently, DCE-MRI has been shown to have prognostic significance. A retrospective analysis on a limited series of newly diagnosed myeloma patients showed a good relationship between IMWG response criteria and imaging response, as evaluated by combining anatomical information from conventional MRI with functional information from DCE and DWI-MRI (43).…”

Section: Metabolic Response and Mrd Evaluation Outside The Bmmentioning

confidence: 99%

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Anderson

Auclair

Kelloff

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools for disease prognostication and management. Assessment of minimal residual disease (MRD) in response to therapy is one of these tools, as longer progression-free survival (PFS) is seen consistently among patients who have achieved MRD negativity. Current therapies lead to unprecedented frequency and depth of response, and next-generation flow and sequencing methods to measure MRD in bone marrow are in use and being developed with sensitivities in the range of 10 to 10 cells. These technologies may be combined with functional imaging to detect MRD outside of bone marrow. Moreover, immune profiling methods are being developed to better understand the immune environment in myeloma and response to immunomodulatory agents while methods for molecular profiling of myeloma cells and circulating DNA in blood are also emerging. With the continued development and standardization of these methodologies, MRD has high potential for use in gaining new drug approvals in myeloma. The FDA has outlined two pathways by which MRD could be qualified as a surrogate endpoint for clinical studies directed at obtaining accelerated approval for new myeloma drugs. Most importantly, better understanding of MRD should also contribute to better treatment monitoring. Potentially, MRD status could be used as a prognostic factor for making treatment decisions and for informing timing of therapeutic interventions. .

show abstract

Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma

Cited by 60 publications

References 22 publications

Benign and malignant orbital lymphoproliferative disorders: Differentiating using multiparametric MRI at 3.0T

Benign and malignant orbital lymphoproliferative disorders: Differentiating using multiparametric MRI at 3.0T

Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Contact Info

Product

Resources

About